Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Reports Preliminary Q4 Revenues of $91M; Beats Expectations

NEW YORK (GenomeWeb News) – Affymetrix today reported preliminary revenues of approximately $91 million for the fourth quarter of 2013, which would beat the consensus analyst estimate of $82.6 million.

The preliminary figure for the quarter would be an 8 percent increase over the $84.3 million the Santa Clara, Calif.-based firm posted in revenues for the fourth quarter of 2012 and includes a one-time licensing payment of $5.3 million from an unnamed diagnostic partner.

Affymetrix said that total revenues for full-year 2013 are expected to be around $329 million, which would be above the average analyst estimate of $320.3 million and an 11 percent improvement from $295.6 million in full-year 2012.

"In 2013 we executed effectively against our three-phase strategic plan and we exited the year as a much stronger company," Affymetrix President and CEO Frank Witney said in a statement. "Over the last 12 months we improved our business’s performance, significantly reduced our senior debt, and increased our overall cash balance."

In morning trading today, shares of Affymetrix on the Nasdaq were up 8 percent at $8.50.

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.